Felocell vaccines by Zoetis are routinely used to immunize cats and kittens.
Felocell 3 (TriCat): Protects against feline viral rhinotracheitis (herpesvirus‑1), feline calicivirus (FCV), and panleukopenia virus (FPV), supporting immunity against prevalent and potentially severe viral conditions in felines
Felocell 4 (TriCat + C): In addition, guards against Chlamydophila felis, further broadening protection during periods of high communal exposure .
These modified-live vaccines are freeze-dried in single-use doses and require reconstitution with the provided sterile diluent. Once administered (either subcutaneously or intramuscularly), they stimulate strong, long-lasting immunity; studies show antibody titers persisting for 12–36 months post-booster
Usage
Target Species: Healthy cats and kittens
Indications: Prevention of feline viral rhinotracheitis, calicivirus, panleukopenia; Chlamydophila felis inclusion with Felocell 4
Vaccination Schedule:
Felocell 3: From 9 weeks, 2 doses 3–4 weeks apart
Felocell 4: From 12 weeks, 2 doses 3–4 weeks apart; for kittens under 12 weeks, revaccinate at 12 weeks
Annual boosters recommended, modified based on risk
Administration:
Reconstitute freeze-dried vial with sterile diluent
Administer 1 mL subcutaneous or intramuscularly
Use low limb injection sites to reduce sarcoma risk
Storage: Keep at 2–7 °C; do not freeze; use vial immediately after reconstitution
Features & Benefits
Broad Protection: Includes core viral antigens, with Felocell 4 offering additional Chlamydophila felis coverage
Rapid & Durable Immunity: Established titers persisting up to 3 years after booster
Human & Feline Safety: Contains gentamicin preservative; low reported adverse reactions (< 1%) such as mild fever or lethargy
Convenient Packaging: Freeze-dried unit doses requiring simple reconstitution
Licensed by Zoetis: Veterinarian-supervised practice ensures correct administration and monitoring
Note
Avoid vaccinating pregnant queens
Mild post-vaccine reactions (fever, anorexia, ocular discharge) reported in ≈1% of cases
In case of severe reaction such as anaphylaxis, administer epinephrine immediately
Injection site selection (low on limb) advised to minimize sarcoma risk
Reviews
There are no reviews yet.